001     139785
005     20210129212659.0
024 7 _ |a 10.1515/hsz-2013-0165
|2 doi
024 7 _ |a 1431-6730
|2 ISSN
024 7 _ |a 1437-4315
|2 ISSN
024 7 _ |a WOS:000325717100002
|2 WOS
024 7 _ |a 2128/18376
|2 Handle
024 7 _ |a altmetric:3121308
|2 altmetric
024 7 _ |a pmid:23787464
|2 pmid
037 _ _ |a FZJ-2013-05757
041 _ _ |a English
082 _ _ |a 540
100 1 _ |a Vasudevan, Ananda Ayyappan Jaguva
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Structural features of antiviral DNA cytidine deaminases
260 _ _ |a Berlin [u.a.]
|c 2013
|b de Gruyter
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1398863252_20150
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |3 POF3_Assignment on 2016-02-29
500 _ _ |a Bitte POF III Topic noch nachtragen.
520 _ _ |a The APOBEC3 (A3) family of cytidine deaminases plays a vital role for innate defense against retroviruses. Lentiviruses such as HIV-1 evolved the Vif protein that triggers A3 protein degradation. There are seven A3 proteins, A3A-A3H, found in humans. All A3 proteins can deaminate cytidines to uridines in single-stranded DNA (ssDNA), generated during viral reverse transcription. A3 proteins have either one or two cytidine deaminase domains (CD). The CDs coordinate a zinc ion, and their amino acid specificity classifies the A3s into A3Z1, A3Z2, and A3Z3. A3 proteins occur as monomers, dimers, and large oligomeric complexes. Studies on the nature of A3 oligomerization, as well as the mode of interaction of A3s with RNA and ssDNA are partially controversial. High-resolution structures of the catalytic CD2 of A3G and A3F as well as of the single CD proteins A3A and A3C have been published recently. The NMR and X-ray crystal structures show globular proteins with six α-helices and five β sheets arranged in a characteristic motif (α1-β1-β2/2'-α2-β3-α3-β4-α4-β5-α5-α6). However, the detailed arrangement and extension of individual structure elements and their relevance for A3 complex formation and activity remains a matter of debate and will be highlighted in this review.
536 _ _ |a 452 - Structural Biology (POF2-452)
|0 G:(DE-HGF)POF2-452
|c POF2-452
|f POF II
|x 0
588 _ _ |a Dataset connected to CrossRef, juser.fz-juelich.de
700 1 _ |a Smits, Sander H. J.
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Höppner, Astrid
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Häussinger, Dieter
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Münk, Carsten
|0 P:(DE-HGF)0
|b 4
|e Corresponding author
700 1 _ |a König, Bernd
|0 P:(DE-Juel1)132009
|b 5
|u fzj
773 _ _ |a 10.1515/hsz-2013-0165
|g Vol. 394, no. 11
|0 PERI:(DE-600)1466062-3
|n 11
|p 1357 - 1370
|t Biological chemistry
|v 394
|y 2013
|x 1431-6730
856 4 _ |u https://juser.fz-juelich.de/record/139785/files/FZJ-2013-05757.pdf
|y OpenAccess
909 _ _ |p VDB
|o oai:juser.fz-juelich.de:139785
909 C O |o oai:juser.fz-juelich.de:139785
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 5
|6 P:(DE-Juel1)132009
913 2 _ |a DE-HGF
|b Key Technologies
|l BioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences
|1 G:(DE-HGF)POF3-550
|0 G:(DE-HGF)POF3-559H
|2 G:(DE-HGF)POF3-500
|v Addenda
|x 0
913 1 _ |a DE-HGF
|b Schlüsseltechnologien
|1 G:(DE-HGF)POF2-450
|0 G:(DE-HGF)POF2-452
|2 G:(DE-HGF)POF2-400
|v Structural Biology
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF2
|l BioSoft
914 1 _ |y 2013
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a JCR/ISI refereed
|0 StatID:(DE-HGF)0010
|2 StatID
915 _ _ |a Allianz-Lizenz
|0 StatID:(DE-HGF)0410
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)ICS-6-20110106
|k ICS-6
|l Strukturbiochemie
|x 0
980 1 _ |a FullTexts
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)ICS-6-20110106
981 _ _ |a I:(DE-Juel1)IBI-7-20200312


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21